From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
 | Serum CgA levels, ng/mL |  | |||
---|---|---|---|---|---|
 | Number | Median | Q1 to Q3 | Minimum to maximum | P |
Subjects | Â | Â | Â | Â | Â |
   Controls | 50 | 77.4 | 57.7 to 99.9 | 28.2 to 196.3 |  |
   NSCLC patients | 88 | 70.4 | 37.9 to 114.6 | 8.7 to 723.8 | 0.337 |
Histotype | Â | Â | Â | Â | Â |
   Adenocarcinoma | 22 | 59.2 | 35.2 to 85.6 | 14.8 to 151.2 |  |
   Squamous | 27 | 80.0 | 41.0 to 128.6 | 14.7 to 386.8 |  |
   Large cell | 10 | 82.1 | 33.7 to 124.0 | 11.4 to 217.9 | 0.465 |
ECOG PS | Â | Â | Â | Â | Â |
   0 | 16 | 37.7 | 27.2 to 68.6 | 8.7 to 103.1 |  |
   1 | 59 | 76.3 | 43.6 to 119.2 | 13.9 to 429.7 |  |
   ≥2 | 13 | 102.8 | 55.8 to 259.4 | 32.1 to 723.8 | 0.0005 |
Stage | Â | Â | Â | Â | Â |
   IIIB | 29 | 44.9 | 29.2 to 85.6 | 13.9 to 259.4 |  |
   IV | 59 | 82.5 | 47.1 to 119.2 | 8.7 to 723.8 | 0.043 |